These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37274182)
1. Association Between Cycle Threshold Value and Vaccination Status Among Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Cases in Ontario, Canada, in December 2021. Ravindran S; Gubbay JB; Cronin K; Sullivan A; Zygmunt A; Johnson K; Buchan SA; Parpia AS Open Forum Infect Dis; 2023 Jun; 10(6):ofad282. PubMed ID: 37274182 [TBL] [Abstract][Full Text] [Related]
2. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads. Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH medRxiv; 2022 Jan; ():. PubMed ID: 35118480 [TBL] [Abstract][Full Text] [Related]
3. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study. Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P; PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956 [TBL] [Abstract][Full Text] [Related]
4. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study. Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506 [TBL] [Abstract][Full Text] [Related]
6. Kinetics of Viral Shedding for Outbreak Surveillance of Emerging Infectious Diseases: Modeling Approach to SARS-CoV-2 Alpha and Omicron Infection. Lin TY; Yen AM; Chen SL; Hsu CY; Lai CC; Luh DL; Yeh YP; Chen TH JMIR Public Health Surveill; 2024 Sep; 10():e54861. PubMed ID: 39298261 [TBL] [Abstract][Full Text] [Related]
7. A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants. Wu D; Ye Y; Tang L; Wang AB; Zhang R; Qian ZH; Wang FZ; Zheng H; Huang C; Lv XY; Wang HF; Zhang YY; Pan JJ; Li YF; Lu MX; Wang CS; Ma YT; An ZJ; Rodewald LE; Yin ZD; Wang XY; Wu ZY; Shao YM Emerg Microbes Infect; 2022 Dec; 11(1):1950-1958. PubMed ID: 35850623 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study. Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678 [TBL] [Abstract][Full Text] [Related]
9. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study. Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536 [TBL] [Abstract][Full Text] [Related]
10. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study. Wan J; Cazer CL; Clarkberg ME; Henderson SG; Lee SE; Meredith GR; Osman M; Shmoys DB; Frazier PI PLoS Med; 2023 Jan; 20(1):e1004153. PubMed ID: 36626376 [TBL] [Abstract][Full Text] [Related]
11. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Puhach O; Adea K; Hulo N; Sattonnet P; Genecand C; Iten A; Jacquérioz F; Kaiser L; Vetter P; Eckerle I; Meyer B Nat Med; 2022 Jul; 28(7):1491-1500. PubMed ID: 35395151 [TBL] [Abstract][Full Text] [Related]
12. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022. Taylor CA; Whitaker M; Anglin O; Milucky J; Patel K; Pham H; Chai SJ; Alden NB; Yousey-Hindes K; Anderson EJ; Teno K; Reeg L; Como-Sabetti K; Bleecker M; Barney G; Bennett NM; Billing LM; Sutton M; Talbot HK; McCaffrey K; Havers FP; MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(12):466-473. PubMed ID: 35324880 [TBL] [Abstract][Full Text] [Related]
13. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China. Yin Z; Fang Q; Wen T; Zheng C; Fu C; Wang S; Li J; Gong X Hum Vaccin Immunother; 2023 Dec; 19(1):2163813. PubMed ID: 36704960 [TBL] [Abstract][Full Text] [Related]
16. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551 [TBL] [Abstract][Full Text] [Related]
17. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination. Pedersen RM; Bang LL; Madsen LW; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE Emerg Infect Dis; 2022 Jun; 28(6):1274-1275. PubMed ID: 35356875 [TBL] [Abstract][Full Text] [Related]
18. Vaccination Is Associated With Shorter Time to Target Cycle Threshold Value in Patients With SARS-CoV-2 Omicron Variant. Wu J; Wei Y; Shen F; Zhu S; Lu Y; Tian X; Zhang P Front Cell Infect Microbiol; 2022; 12():943407. PubMed ID: 35873164 [TBL] [Abstract][Full Text] [Related]
19. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort. Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871 [TBL] [Abstract][Full Text] [Related]
20. [Analysis of clinical characteristics of 362 vaccinated or unvaccinated patients infected by novel coronavirus Omicron variant]. Feng Q; Wang Z; Yu H; Shi L; Xu L Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 May; 34(5):459-464. PubMed ID: 35728844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]